Impact of Antiretroviral Therapy on Cardiac Biomarkers

Completed

Conditions studied: HIV Infections

In brief

Cardiovascular risk appears to be linked to some degree with inflammation. HIV medications have been linked with cardiovascular risk. In this study we will be measuring levels of chemicals in the body associated with inflammation before and after starting HIV medications in patients with HIV. We hope to understand what happens to these chemicals once a patient with HIV is started on these medications to understand their role in cardiovascular risk.

Key facts

Study ID

NCT00641888

Run by

University of California, Davis

People needed

40

Starts

2008-03-01

Expected to finish

2014-10-01

Last updated by the study team

2017-07-11

Who can join

Age: 18 and older, up to 69. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Patients with a CD4 count between 200-400 planning on initiating antiretrovirals.

You may not qualify if…

• Pregnancy,
• Recent discontinuation of an antiretroviral within the past 30 days,
• Active intravenous drug use,
• Acute febrile illness with temperature > 100 F,
• Diagnosis or symptoms of acute infection within the past 30 days,
• Opportunistic infection or surgical procedure within the past 60 days,
• Myocardial infarction within the last 30 days,
• Renal disease (CKD Stages 3-5), and
• Unstable liver disease.

Where it is running

• University of California, Davis — Sacramento, California, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.